We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
XVIVO.ST

Price
269.60
Stock movement down
-3.00 (-1.10%)
Company name
Xvivo Perfusion AB
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Medical Devices
Market cap
8.49B
Ent value
8.24B
Price/Sales
11.31
Price/Book
4.08
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
41.57
Forward P/E
44.31
PEG
-
EPS growth
44.77%
1 year return
-5.57%
3 year return
0.32%
5 year return
15.88%
10 year return
20.15%
Last updated: 2025-04-12

DIVIDENDS

XVIVO.ST does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E41.57
Price to OCF126.12
Price to FCF-
Price to EBITDA68.00
EV to EBITDA65.96

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales11.31
Price to Book4.08
EV to Sales10.97

FINANCIALS

Per share

Loading...
Per share data
Current share count31.50M
EPS (TTM)6.45
FCF per share (TTM)-0.40

Income statement

Loading...
Income statement data
Revenue (TTM)750.59M
Gross profit (TTM)529.26M
Operating income (TTM)47.73M
Net income (TTM)204.27M
EPS (TTM)6.45
EPS (1y forward)6.08

Margins

Loading...
Margins data
Gross margin (TTM)70.51%
Operating margin (TTM)6.36%
Profit margin (TTM)27.21%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash449.98M
Net receivables187.96M
Total current assets828.06M
Goodwill597.64M
Intangible assets687.97M
Property, plant and equipment0.00
Total assets2.28B
Accounts payable140.94M
Short/Current long term debt9.84M
Total current liabilities150.78M
Total liabilities195.02M
Shareholder's equity2.08B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)67.33M
Capital expenditures (TTM)79.89M
Free cash flow (TTM)-12.56M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity9.81%
Return on Assets8.97%
Return on Invested Capital9.76%
Cash Return on Invested Capital-0.60%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open274.00
Daily high275.60
Daily low261.20
Daily Volume99K
All-time high539.00
1y analyst estimate538.17
Beta2.13
EPS (TTM)6.45
Dividend per share-
Ex-div date-
Next earnings date22 Apr 2025

Downside potential

Loading...
Downside potential data
XVIVO.STS&P500
Current price drop from All-time high-49.98%-12.89%
Highest price drop-71.38%-56.47%
Date of highest drop11 Oct 20229 Mar 2009
Avg drop from high-18.11%-11.07%
Avg time to new high19 days12 days
Max time to new high696 days1805 days
COMPANY DETAILS
XVIVO.ST (Xvivo Perfusion AB) company logo
Marketcap
8.49B
Marketcap category
Mid-cap
Description
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.
Employees
161
Investor relations
-
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attached...
April 2, 2025
GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 /XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives noti...
March 20, 2025
As European markets navigate the complexities of U.S. trade tariffs and fluctuating monetary policies, the pan-European STOXX Europe 600 Index recently experienced a slight decline, reflecting broader...
March 19, 2025
GOTHENBURG, SE / ACCESSWIRE / January 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Fourth quarter 2024 (October 1 - December 31) • Net sales amounted to SEK 227.6 million (155.7), corr...
January 28, 2025
GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report 20...
January 13, 2025
Amid a complex global market environment, major U.S. indices have shown mixed results with growth stocks outperforming value stocks significantly, while geopolitical events and economic reports contin...
December 13, 2024
GOTHENBURG, SE / ACCESSWIRE / November 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO's innovative heart technology is currently under investigation in the US clinical trial "PRESE...
November 25, 2024
In the current global market landscape, small-cap stocks have experienced a mixed performance, with the Russell 2000 index showing a decline amidst broader market volatility influenced by political ch...
November 21, 2024
GOTHENBURG, SWEDEN / ACCESSWIRE / November 14, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The Board of Directors of XVIVO Perfusion AB (publ) ("XVIVO") has today appointed Lena Hagman as...
November 14, 2024
In the wake of a "red sweep" in the U.S. elections, global markets have experienced a notable rally, with major benchmarks reaching record highs as investors anticipate potential economic growth drive...
November 12, 2024
Next page